ES2169857T3 - USE OF TETRAHIDRO-BETA-CARBOLINAS DERIVATIVES AS ANTIMETASTATIC AGENTS. - Google Patents

USE OF TETRAHIDRO-BETA-CARBOLINAS DERIVATIVES AS ANTIMETASTATIC AGENTS.

Info

Publication number
ES2169857T3
ES2169857T3 ES97916410T ES97916410T ES2169857T3 ES 2169857 T3 ES2169857 T3 ES 2169857T3 ES 97916410 T ES97916410 T ES 97916410T ES 97916410 T ES97916410 T ES 97916410T ES 2169857 T3 ES2169857 T3 ES 2169857T3
Authority
ES
Spain
Prior art keywords
pct
beta
derivatives
carbolinas
tetrahidro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97916410T
Other languages
Spanish (es)
Inventor
Silvano Spinelli
Ernesto Menta
Hans-Willi Krell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITMI960664 external-priority patent/IT1283574B1/en
Priority claimed from IT96MI002241 external-priority patent/IT1286060B1/en
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2169857T3 publication Critical patent/ES2169857T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

PCT No. PCT/EP97/01582 Sec. 371 Date Nov. 12, 1998 Sec. 102(e) Date Nov. 12, 1998 PCT Filed Mar. 27, 1997 PCT Pub. No. WO97/37658 PCT Pub. Date Oct. 16, 1997The present invention concerns the use of beta-carboline derivatives of formula I bearing at least a free or esterified carboxylic group on the piperidine ring, for the preparation of pharmaceutical compositions having antimetastatic properties.
ES97916410T 1996-04-04 1997-03-27 USE OF TETRAHIDRO-BETA-CARBOLINAS DERIVATIVES AS ANTIMETASTATIC AGENTS. Expired - Lifetime ES2169857T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI960664 IT1283574B1 (en) 1996-04-04 1996-04-04 Use of tetra:hydro-beta-carboline derivatives - for preparation of medicaments having anti-metastatic activity or tumour invasion or matrix metallo-proteinase inhibitory activity
IT96MI002241 IT1286060B1 (en) 1996-10-29 1996-10-29 Use of tetra:hydro-beta-carboline derivatives - for preparation of medicaments having anti-metastatic activity or tumour invasion or matrix metallo-proteinase inhibitory activity

Publications (1)

Publication Number Publication Date
ES2169857T3 true ES2169857T3 (en) 2002-07-16

Family

ID=26331376

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97916410T Expired - Lifetime ES2169857T3 (en) 1996-04-04 1997-03-27 USE OF TETRAHIDRO-BETA-CARBOLINAS DERIVATIVES AS ANTIMETASTATIC AGENTS.

Country Status (15)

Country Link
US (1) US6069150A (en)
EP (1) EP0891187B1 (en)
JP (1) JP2000508302A (en)
KR (1) KR20000005175A (en)
CN (1) CN1113648C (en)
AT (1) ATE212549T1 (en)
AU (1) AU710079B2 (en)
BR (1) BR9708480A (en)
CA (1) CA2250898A1 (en)
DE (1) DE69710182T2 (en)
DK (1) DK0891187T3 (en)
ES (1) ES2169857T3 (en)
PT (1) PT891187E (en)
TR (1) TR199801970T2 (en)
WO (1) WO1997037658A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040253891A1 (en) * 2000-09-12 2004-12-16 Schierenbeck Alan W. Composite structure for protective garment
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
WO2002088123A1 (en) * 2001-04-25 2002-11-07 Lilly Icos Llc Chemical compounds
US6933303B2 (en) * 2001-10-19 2005-08-23 Transtech Pharma, Inc. Heteroaryl-fused nitrogen heterocycles as therapeutic agents
CN100503607C (en) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 Yageine derivative compounds and their uses
US20050101623A1 (en) * 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
AU2005206570A1 (en) * 2004-01-23 2005-08-04 Novartis Vaccines And Diagnostics, Inc. Tetrahydrocarboline compounds as anticancer agents
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
JP4857452B2 (en) * 2004-03-15 2012-01-18 ピーティーシー セラピューティクス，インコーポレーテッド Carboline derivatives useful for inhibiting angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
CN100360129C (en) * 2004-09-03 2008-01-09 首都医科大学 Dehydro eleagnine derivative, its synthesizing method and use
WO2006070385A1 (en) * 2004-12-27 2006-07-06 Council Of Scientific And Industrial Research 2-alkyl/aryl sulphonyl-1,2,3,4-tetrahydro-9h-pyrido (3,4-b) indole-3-carboxylic acid esters/amides useful as antithrombotic agents
ITMI20071163A1 (en) * 2007-06-08 2008-12-09 C4T S C A R L ARILSOLFONAMIDES DELA BETA-CARBOLINE METHOD FOR PREPARING THEM AND COMPOSITION THAT INCLUDES THEM
TWI443098B (en) 2008-03-24 2014-07-01 Medivation Technologies Inc Pyrido[3,4-b]indoles and methods of use
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
JP2012528181A (en) 2009-05-27 2012-11-12 ピーティーシー セラピューティクス，インコーポレーテッド Method for producing substituted tetrahydro β-carboline
EP3718405A1 (en) 2009-05-27 2020-10-07 PTC Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
CN101906102B (en) * 2009-06-02 2012-08-29 首都医科大学 Beta-carboline alkaloid derivative, preparation method and application thereof
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
CN104744460B (en) 2013-12-30 2017-06-16 南开大学 β carbolines, dihydro β carbolines and tetrahydro-beta-carboline alcaloid-derivatives and preparation method thereof and the application in terms of preventing and treating plant virus, sterilization, desinsection
JP6616790B2 (en) 2014-06-27 2019-12-04 ノグラ ファーマ リミテッド Aryl receptor modulators and methods of making and using the same
EP3915542B1 (en) 2014-12-23 2023-11-22 Dyve Biosciences, Inc. Formulations for transdermal administration
EP3436005A4 (en) * 2016-03-29 2020-07-22 Georgia State University Research Foundation, Inc. Calcium sensing receptors, ligands, compositions, and methods of use
AU2018255294B2 (en) * 2017-04-17 2022-07-28 Ampersand Biopharmaceuticals, Llc Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
KR20200035292A (en) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. DHODH inhibitors for use in the treatment of blood cancer
WO2019055880A2 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Method of administration and treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3395M (en) * 1963-07-30 1965-06-28 Roussel Uclaf New drug, in particular for the treatment of neurodepressive states and anxiety psychoses.
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4539407A (en) * 1983-12-13 1985-09-03 American Home Products Corporation β-Carboline anticonvulsants
US5162336A (en) * 1990-06-21 1992-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Tetrahydro-pyrido-indoles as cholecystokinin and gastrin antagonists
US5244905A (en) * 1990-08-31 1993-09-14 Warner-Lambert Company N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives
CN1105799A (en) * 1993-03-18 1995-07-26 大制药株式会社 Carbostyril derivatives as matrix metalloproteinases inhibitors
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds

Also Published As

Publication number Publication date
DE69710182T2 (en) 2002-08-29
EP0891187A1 (en) 1999-01-20
KR20000005175A (en) 2000-01-25
CN1215333A (en) 1999-04-28
US6069150A (en) 2000-05-30
JP2000508302A (en) 2000-07-04
AU2506997A (en) 1997-10-29
ATE212549T1 (en) 2002-02-15
EP0891187B1 (en) 2002-01-30
PT891187E (en) 2002-06-28
CN1113648C (en) 2003-07-09
DE69710182D1 (en) 2002-03-14
DK0891187T3 (en) 2002-04-29
AU710079B2 (en) 1999-09-16
TR199801970T2 (en) 2000-10-23
WO1997037658A1 (en) 1997-10-16
BR9708480A (en) 1999-04-13
CA2250898A1 (en) 1997-10-16

Similar Documents

Publication Publication Date Title
ES2169857T3 (en) USE OF TETRAHIDRO-BETA-CARBOLINAS DERIVATIVES AS ANTIMETASTATIC AGENTS.
ES2158537T3 (en) DERIVATIVES OF CYCLOPROPILALCANOIC ACIDS.
DE69621831T2 (en) PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS
ES2162676T3 (en) PHENYLENE DERIVATIVES REPLACED IN META AND ITS USE AS ANTAGONISTS OR INHIBITORS OF INTEGRINA ALFAV, BETA3.
TR200101961T2 (en) 1,2-ring quinoline derivatives
BR9813228A (en) Formulation of 2-methyl-thieno-benzodiazepine
CO4930259A1 (en) DERIVATIVES 6,6-HETEROBICICLICOS SUBSTITUTED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ES2179318T3 (en) DERIVATIVES OF CINAMIC ACID AND ITS USE AS INTEGRINE ANTAGONISTS.
ES2160949T3 (en) DERIVATIVES OF PHENYLENE-SULFONAMIDE REPLACED IN META.
EP1334719A3 (en) Pentafluorobenzenesulfonamides and analogs
EA200100774A1 (en) HYDRONIC
ES2193154T3 (en) PROCEDURE FOR THE PREPARATION OF 9-DEOXOTAXANS.
TR200000025T2 (en) Azetidinylpropylpiperidine derivatives, their use as antagonists of the crown.
ES2193414T3 (en) DIHYDROBENZOFURANS SUBSTITUTED AS INHIBITORS OF THE PDE.
TR199801268T2 (en) 3-Azetidinylalkylpiperidines or pyrrolidines as tachykinin antagonists.
PT1119359E (en) FORMULATION OF 2-METHYL-TIENE-BENZODIAZEPINE
BG102661A (en) Benzo/o/quinolysine derivatives, their preparation and application as 5a-reductase inhibitors
DE69828390D1 (en) DIAMINOTRIFLUOROMETHYLPYRIMIDIN DERIVATIVES ANTICREASIC COMPOSITION
NO971991L (en) Heterocycle-substituted propenoic acid derivatives as NMDA antagonists
DK0883628T3 (en) 17beta (2-oxo-tetrahydrofuran-4-yl) thioandrosteine derivatives (17beta (gamma-butyric acid lactone) thiode derivatives) for treatment
PT914129E (en) USE OF ASPIROCLORUS OR ITS DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS
MY111366A (en) Piperdine derivatives.
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
TR199802419T2 (en) Brand New Pyridazine Compounds.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 891187

Country of ref document: ES